Elacridar (GF120918, GW0918, GG918, GW120918)，又称依克立达，是可口服的P-glycoprotein (P-gp)选择性抑制剂，IC₅₀值为193 nM，也是乳腺癌抗性蛋白(BCRP)的抑制剂。

参考文献

[1] Sato H, et al. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells. Eur J Pharmacol. 2015 Jan 5;746:258-66.

[2] Sane R, et al. Brain distribution and bioavailability of elacridar after different routes of administration in the mouse. Drug Metab Dispos. 2012 Aug;40(8):1612-9.

冰袋运输。粉末直接保存于-25~-15℃，有效期3年。建议溶解分装后于-25~-15℃干燥保存，避免反复冻融。